Email : info@otcjournal.com
URL : http://www.otcjournal.com
To
OTC Journal Members:
 |
Our
Apologies |
 |
Many apologies to our valued members
who were expecting to read a new profile in today's edition. Unfortunately,
it's release has been either delayed indefinitely, or canceled.
This is the second Friday in a row
we have announced a special event and failed to deliver the goods. Last
week's delayed release was due to the failure on the company's part to
deliver a "Trading Alert" worthy event. This week there is a contractual
issue.
In these tenuous times it is important
to err to the side of caution. Therefore, when events do not fall into
place properly, we will always be conservative in our practices, even though
we feature extremely risky companies.
 |
Calypte Biomed
(OTC BB: CALY)- Rocketing up the Charts |
|
Calypte Biomed was the subject
of our
May 31st Trading Alert. This company has the only FDA Approved urine
based test for the HIV virus. Calypte had announced it would be
closing down operations back in April, which caused the stock to trade
down as low as $.03. Shareholders took the reins, brought in new management
and new capital, and the stock has rebounded dramatically.
We alerted members in this past Wednesday's
edition that the stock was nearing our short term price target of $.20,
up 45% from our Trading Alert entry price in less than a month.
On Thursday the stock sliced through the $.20 level like a fighter
jet through the sound barrier, and today closed at $.28, up 102%
from our entry point.
To paraphrase the great American
humorist Mark Twain, "The Death of the Stock Market Has Been Greatly
Exaggerated". Also- For those who sold this stock at $.03- "The
death of Calypte has been greatly exaggerated". What a refreshing
change to have a nice winner for our members in the midst of all this doom
and gloom.
We had no idea the stock was destined
to trade this well. Congratulations to members who took a position. If
you haven't sold, you're doing well. If you have sold, you can always get
back in.
Since issuing our Trading Alert,
the company has announced the resumption of normal production, acquiring
the rights to distribute a urine based test for liver function, and a non-exclusive
world wide distribution agreement for its products.
Rumors are circulating concerning
the company, but we will only report the facts as they become publicly
disclosed.
The company is not a start up. They
were able to achieve $6.8 million in revenues in 2001. Over $90 million
has been invested in the company to date, and they are just at the beginning
of the sales cycle for their unique products. To learn more about the company,
you can read our May 31st edition by clicking
here.
Buy, Sell, Or Do Nothing? Frankly,
we don't know. Events are happening much faster than we anticipated. Calypte
has less than an $18 million market capitalization at these levels, which
suggests there is a lot more upside in the stock.
Nice runs like this are usually met
with pullbacks, some sideways trading, then a resumption of the climb north.
If you're a buyer at these levels you should be mentally prepared to hold
through a slight pullback. Stand by for more coverage after the 4th of
July weekend. We might have lucked into an exciting situation to keep you
on the edge of your chair during the long, boring summer days.
|
An
Observation |
|
Despite the severe turbulence in
the mid and large cap markets, it has not escaped our attention that investors
still love a good old fashioned penny stock.
There is no precise definition of
a penny stock. Now commonly called a "microcap", this term refers to any
stock under a $100 million market capitalization. We view any stock which
trades under $1 as a penny stock, and they are usually also microcaps.
Penny stocks appeal to the same beast
within us that drives us to the casinos in Las Vegas. We love the risk,
and we love the occasional win. We know they are inherently risky, so we
can shoulder the losses more easily. Penny stocks are also looked down
on by main stream Wall Street, which is probably one of the reasons investors
still have an appetite for these obscure companies. They seem to be immune
from the daily news of fraud and deceit which infect the high flyers of
the 90's.
We expect the overall market to trade
sideways this summer on lighter volume, setting up for a return of the
Bull in the fall. Therefore, it makes sense for us to focus our efforts
on the overlooked penny stock for the next couple of months. This seems
to be where the action is for now. Stand by for more editions featuring
penny stocks.
Charts Provided Courtesy
Of TradePortal.com
The OTC Journal is
a proud partner of the SwingWire.com
Online Investment Community. A next generation Online Analyst Exchange
providing Members the ability to search, review, track and monitor some
of the Internet's best Online CAs (CyberAnalysts). Members
have the opportunity to potentially achieve higher
returns by viewing top performing portfolios
and receiving real-time alerts from favorite CAs.
SwingWire.com
also has a lucrative incentive model for experienced investors and traders
who consistently outperform the market. Share market ideas with other like-minded
investors, establish a proven track record, provide insightful commentary,
attract followers and ultimately become one of the Internet's highest paid
and most sought after CyberAnalysts!
Click
here to receive your FREE 30-Day Trial Membership with no further obligation.
Sign Up Today!
|
